Bionest Immuno-Oncology Capabilities

Bionest Immuno-Oncology Capabilities
1
ARE YOU POSITIONED FOR SUCCESS
IN NEXT-GENERATION IMMUNOONCOLOGY?
IO Frenzy Raises Key Strategic Questions
As IO moves beyond the first generation of Yervoy, Opdivo, and
Keytruda, more companies are investing in IO…
…opportunities abound, but the field is moving fast and opportunities
will close quickly.
2 approved
PD-1 / PD-L1
Ph. I-II =
3 Ph. III
Next-Gen
Checkpoints:
IDO-1, OX-40, GITR,
LAG-3, TIM-3
How to differentiate my PD-(L)1?
10+
Biomarker or no biomarker?
What combination strategy?
What opportunity for my early stage PD-(L)1?
15+ in clinical trials
How can I move quickly?
Biomarker or no biomarker?
>40 pre-clinical
What opportunities for my asset?
Novel-combo? PD-(L)1 combo? Mono?
Bionest Immuno-Oncology Capabilities
2016 – Slide 3
Keys to a Successful IO Strategy
KNOW THE OPPORTUNITIES
The IO space is becoming increasingly crowded, and opportunity windows may
not remain open for long
DEFINE ALTERNATIVES TO ADDRESS HIGH
IMPACT OPPORTUNITIES
Evaluate when and where to leverage combinations, whether you need a
biomarker / CDx strategy, and how to maximize your asset or portfolio value
BUILD A ROBUST IO PORTFOLIO…
OR BECOME PARTNER OF CHOICE
Developing an IO focused Corporate Development Strategy is critical, whether
you plan to build internally, invest in external opportunities, or focus on
external collaborations
Bionest Immuno-Oncology Capabilities
2016 – Slide 4
What Can Bionest Do For You?
MAPPING
OPPORTUNITIES
 In-depth IO landscape
assessment
DEFINE STRATEGIC
ALTERNATIVES
 How to address high
impact opportunities
 Combination strategy
 Competitor strategies
and future scenarios
 Mapping & prioritization
of opportunity areas
 Future landscape and
timing of opportunity
windows
CORPORATE
DEVELOPMENT STRATEGY
 Biomarker / CDx
strategy
 How and when to
leverage your internal
PD-(L)1
 Differentiating delivery
/ formulation strategy
Bionest Immuno-Oncology Capabilities
2016 – Slide 5
 Building a competitive
IO portfolio
 Search & Scout to
identify external
opportunities
 Partnering strategy
Bionest has a Strong Track Record in Immuno-Oncology
Multiple Big Pharma and Biotech Clients
Bionest Has Worked Extensively in Immuno-Oncology
In Multiple Treatment Modalities...
… And Across Various Therapeutic Areas
Checkpoint Modulators
CAR-T / TCR
BiTEs
Vaccines
Solid Tumors
Melanoma, NSCLC, RCC, H&N, Gastric, HCC, CRC,
Breast, Ovarian, Prostate, Glioblastoma etc.
Heme Malignancies
B and T Cell NHL, CLL, MDS, Multiple Myeloma,
Leukemia, etc.
Numerous Companies Have Trusted Bionest With IO-Related Projects
Bionest Immuno-Oncology Capabilities
2016 – Slide 6
Bionest has a Strong Track Record in Immuno-Oncology
Selected Project Examples
Immuno-Oncology Portfolio Strategy
Immuno-Oncology Combination Strategy
Company Strategies
Strategy for Opportunity Area #1



In-depth review of IO landscape and clear
understanding of opportunity areas, including
competition, timelines, and efficacy
requirements
Workshop session to prioritize opportunities
and define optimal strategy to maximize
success of the program
Recommended IO strategy including a
presentation for Sr. Management

Developed understanding of the evolving IO
combination landscape

Identified opportunities to enhance the value
proposition of each of the client’s therapies to
drive differentiation and gain leadership

Bionest prioritized potential combination
partners and provided rationales for a
mutually beneficial partnership
Bionest Immuno-Oncology Capabilities
2016 – Slide 7
Bionest has a Strong Track Record in Immuno-Oncology
Extensive Thought Leadership
Selected Articles and Presentations
“Immunotherapy: Big Pharma’s Seductive Embrace”
IN VIVO, Dec. 2014
“Companies are…setting up combination trials early in
clinical development…This notion of seeking synergy from
the get-go is a dramatic shift in how cancer drugs are
developed, with strong implications for partnering, pricing,
and life cycle management”
SEPTEMBER 2015
2016
2016
“Immuno-Oncology Brings New
Opportunities for Developers of
Targeted Cytotoxics”
“Time to be Savvy for
Next-Generation
Immuno-oncology”
“Can CDx Save the NextGeneration of ImmunoOncology?”
Personalized Medicine in Oncology
Article in Progress
Article in Progress
Opdivo and Keytruda have been
approved and incorporated into
standard-of-care in several
indications, with other
approvals on the horizon.
Companies are capitalizing on
immuno-oncology’s (IO)
success, pushing forward with
additional PD-1/L1 inhibitors as
well as next-generation
therapies. These companies face
a highly competitive and
complex market, where past
strategies may prove obsolete
and more savvy bets may drive
success.
First-generation IO agents
have, for the most part, been
widely approved. After the
focus on precision medicine for
molecular therapies, it has
failed to make its way into IO
thus far. However, the IO space
is poised to become increasingly
complex. Experts recognize
that biomarker approaches will
become increasingly important,
but how this will play out and
who will drive this remains to
be seen.
To read these articles and more, visit http://bionest.com/publications/publications/
Bionest Immuno-Oncology Capabilities
2016 – Slide 8
Bionest is a Global Consulting Firm With an Experienced Management Team
America
Europe
Bob Easton
Co-Chairman
New York
Alain Gilbert
Co-Chairman
Paris
Olivier Lesueur
Managing Director
New York
Anne-Sophie
Demange
Manager
Paris
Asia
Yasuhiro Komatsu
Senior Advisor
Tokyo
Additional Strategic partner
in China
Mary Koto
Founder
San Diego
Rachel Laing
Manager
Basel
Additional Strategic partner
in South America
Bionest Professional Staff: Majority of the team have a Ph.D. and / or MBA degree
Bionest Immuno-Oncology Capabilities
2016 – Slide 9
380 Lexington Ave, 43rd Floor
New York, NY 10168
USA
Tel: +1 612 212 3030
19, rue du Général Foy
75008 Paris
France
Tel: +33 1 58 05 14 00
[email protected]
www.bionest.com
Bionest Immuno-Oncology Capabilities
2016 – Slide 10
1010